– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast…
– SPC3649 successfully inhibits miR-122, a microRNA important for hepatitis C viral replication, thereby significantly reducing hepatitis C virus in the bloodstream in chimpanzees chronically infected with the hepatitis C virus Hoersholm, Denmark/San Diego, California — A study published…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it will receive further milestone payments totalling €3 million from Boehringer Ingelheim, triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. Ablynx will now have…
– Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene's REVLIMID® Growing body of evidence in hematological malignancies supports REVLIMID® enhanced…
– Abbott (NYSE: ABT) and BG Medicine, Inc. today announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott's ARCHITECT immunochemistry…
– -US Subsidiary Supports Expanding Opportunities for Symphogen’s Novel Antibody Pipeline and Discovery and Expression Platforms- COPENHAGEN, Denmark and PRINCETON, NJ - Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax,…
– SUNNYVALE, Calif. — FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the U.S. launch of the Over the Wire (OTW) delivery platform for the CROSSER® 14S and CROSSER® 14P peripheral CTO…
– HENT, Belgium - Ablynx [Euronext Brussels: ABLX], today announced that it will receive milestone payments totalling €3 million from Boehringer Ingelheim triggered as part of its strategic alliance for the development and commercialisation of Nanobodies®. This is the second time Ablynx…
– SUNNYVALE, Calif. — FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), has launched the FlowMate Injector, which dramatically simplifies central lumen crossing of CTOs using the CROSSER CTO Recanalization…
– HEIDELBERG, Germany -- mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, today announced the successful closing of a EUR 16.6 million (USD 23 million) Series E investment. The round was subscribed by an international syndicate of both new and…
– Denmark-based Santaris Pharma A/S appoints leading RNA industry expert Art Levin Ph.D. as President of US operations and Chief Development Officer Utilizing its proprietary RNA chemistry - Locked Nucleic Acid (LNA) –and Drug Discovery Engine, the US subsidiary aims to foster…
– Germany - Pieris AG announced that they have entered into a collaboration agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal of developing agents for…
– Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic…
– LEIDEN, THE NETHERLANDS and SEATTLE, WA - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a EUR 8 million series B investment. The financing round was led by new investor Gilde Healthcare…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced the positive results from its double-blind, randomized, placebo-controlled, single and multiple dose Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody® that selectively targets…
– Seasoned Executive will Drive Business Development Efforts for Antibody Discovery and Expression Platforms COPENHAGEN, Denmark - Symphogen A/S today announced that Adriann Sax has joined the company’s management team as Chief Business Officer. Ms. Sax brings to Symphogen extensive…
– Marseilles, France - Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports positive results for its first Phase IIa clinical trial with IPH 1101 (a small-molecule ?? T cell agonist) in patients with type C viral hepatitis (“HCV”). In this open-label trial, two injections of IPH…
– Humana Health-Plan Members in Chicago and South Florida Volunteered to Participate in Study LOUISVILLE, Ky. & WALTHAM, Mass - Imagine if doctors could easily detect the conditions that cause many heart attacks or strokes – in time to prevent the life-threatening attacks. BG Medicine…
– On June 24, 2009 Conatus Pharmaceuticals Inc. (San Diego, USA) announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom…
– International Expert Panel Recommends Use of Multigene Profiling Assays and Finds Intermediate Scores Lack Clinical Utility HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS - Agendia, a world leader in molecular cancer diagnostics, today announced the inclusion of its breast…
– Oxford – Chroma Therapeutics Limited, a UK based biotechnology company focused on small molecule cancer and inflammation therapeutics, announces it has completed a £15 million Series D financing round. Chroma will use the funds to develop its aminopeptidase inhibitor, tosedostat (CHR-2797)…
– Chroma Therapeutics Limited and GlaxoSmithKline form alliance to develop novel macrophage-targeted drugs Oxford and London, UK – Chroma Therapeutics Limited and GlaxoSmithKline, through its Center of Excellence for External Drug Discovery (CEEDD), (LSE: GSK) announced today a collaboration…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, announces the initiation of a Phase II study of its lead compound, APD405, in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant…
– Copenhagen, Denmark - Santaris Pharma today announced that the cancer drug EZN-2968 – an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S – was well tolerated and showed early signs of clinical benefit in previously treated cancer patients…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The laboratory is fully-licensed and compliant with the Clinical Laboratory…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, announced the initiation of a Phase IIa study of its product APD209 to treat cachexia in cancer patients. APD209 has been designed to target specific problems experienced…
– WALTHAM, Mass. – (BUSINESS WIRE) - BG Medicine Inc. (BGM), a developer of novel, biomarker-based diagnostic products, today announced the launch of the Galectin-3 Website (www.galectin-3.com) which will provide an array of research materials associated with galectin-3. Galectins…
– COPENHAGEN, Denmark and EMERYVILLE, CA - Symphogen A/S and Origen Therapeutics today announced a strategic collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets. Origen will use its avian transgenic technology…
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS – Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Dr. Albert A. (Al) Luderer to its Supervisory Board. Dr. Luderer has more than 30 years of experience in in vitro medical diagnostics,…
– Waltham, Mass. – BG Medicine Inc. (BGM) today announced that Doug White has joined the organization as Executive Vice President & General Manager, Diagnostics. In this newly created role, Mr. White will be responsible for the strategic direction and overall management of the company’s…
– HUNTINGTON BEACH, California, and AMSTERDAM, /PRNewswire/ - Findings Published in Peer-Reviewed Journal, Breast Cancer Research and Treatment Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, today announced that Ian Kent has joined its Board of Directors as Non-executive Chairman. Ian has a wealth of corporate experience having acted as Chairman and Non-executive…
– Munich, Germany – IDEA AG today announced the granting of a new US patent (7,473,432) that covers the recently improved Transfersome® technology and the Company’s lead product, Diractin®, which is already approved in Switzerland and in the final stage (phase III) of clinical development…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its drug discovery and development alliance with Novartis has been extended for another year. Under…
– COPENHAGEN, Denmark - Symphogen A/S today announced the closing of a € 33 million (approximately U.S. $44 million) financing. Existing investors participated in the round, which was led by Essex Woodlands Health Ventures. The financing will be used to mature the company’s product…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, today announced that it will receive milestone payments totalling €3 million from Boehringer Ingelheim triggered as…
– Expansion of management team announced to support program success Freising-Weihenstephan, Germany – Pieris AG, a bio-pharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development…
– COPENHAGEN, Denmark and PALO ALTO, Calif., U.S. - Symphogen A/S and Receptor BioLogix, Inc ,( Receptor). announced today that Symphogen has acquired the technology and programs of Receptor BioLogix. Symphogen is a leader in developing recombinant polyclonal antibodies, a new class…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, has expanded its musculoskeletal research portfolio by transferring in-house full ownership of a bone disorder R&D…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today two significant advances achieved with its Nanobody® platform. In the first, it has shown that anti-viral…
– Collegeville, Pa., & Hoersholm, Denmark — Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Santaris Pharma today announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma’s…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that it has appointed Dr Debbie Law, as its Chief Scientific Officer. Dr Law has over thirteen years…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of supportive care drugs, has successfully completed its first clinical trial, a Phase I study of its lead product candidate APD 405. Acacia is one of the few companies focused on supportive care,…